Josh Stoneking

Josh Stoneking is an accomplished executive in the specialty pharmacy and infusion sector, with extensive experience in driving growth and operational excellence. As Senior Vice President at BioMatrix Specialty Infusion Pharmacy, Josh directed national operations, achieving over $500 million in annual revenue and 32% year-over-year growth. Previous roles include overseeing pharmaceutical partnerships and scaling infusion services to triple market share. At Optum, Josh was instrumental in launching the 503A oncology compounding division, establishing a $100 million revenue stream in under two years. Education includes a Doctorate in Pharmacy and a Bachelor of Science in Exercise Physiology, both from West Virginia University School of Medicine.